Briacell Therapeutics Corp - Asset Resilience Ratio
Briacell Therapeutics Corp (BCTX) has an Asset Resilience Ratio of 0.00% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Briacell Therapeutics Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Briacell Therapeutics Corp's Asset Resilience Ratio has changed over time. See how leveraged is Briacell Therapeutics Corp's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Briacell Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BCTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Briacell Therapeutics Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Briacell Therapeutics Corp Industry Peers by Asset Resilience Ratio
Compare Briacell Therapeutics Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Briacell Therapeutics Corp (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Briacell Therapeutics Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-07-31 | 34.05% | $10.14 Million | $29.77 Million | +34.05pp |
| 2024-07-31 | 0.00% | $175.00 | $8.15 Million | -45.04pp |
| 2018-07-31 | 45.04% | $1.03 Million | $2.28 Million | +8.27pp |
| 2017-07-31 | 36.78% | $601.76K | $1.64 Million | -29.92pp |
| 2015-07-31 | 66.70% | $851.24K | $1.28 Million | +61.34pp |
| 2013-07-31 | 5.36% | $504.49K | $9.41 Million | -0.11pp |
| 2012-07-31 | 5.48% | $564.98K | $10.32 Million | -3.48pp |
| 2011-07-31 | 8.96% | $1.11 Million | $12.35 Million | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more